The Three Battles Every Oral Peptide Must Win
Why turning Ozempic into a tablet is one of pharma’s hardest engineering problems
Semaglutide already survives a week in the bloodstream. Swallow it as a tablet, though, and almost none of it would ever get there. The reason has nothing to do with the drug being weak — it has to do with what stands between a swallowed dose and the blood: an acid bath, a locked door, and a body built to break peptides apart on sight.
By Ibumix · 6-minute read
Imagine spending twenty years developing one of the most effective medicines in modern history. It lowers blood sugar. It reduces appetite. It helps people lose significant amounts of weight, and lowers cardiovascular risk in many patients along the way. Doctors want to prescribe it. Patients want to take it.
The only problem: most people have to inject it.
At first glance that seems strange. Modern medicine swallows its way through headaches, infections, high blood pressure and high cholesterol without a second thought — injections feel like the exception, not the rule. So why is semaglutide, the molecule behind Ozempic and Wegovy, different?
The answer has nothing to do with the medicine being too powerful for a pill. It comes down to one fact: semaglutide is a peptide, and peptides live in one of the most hostile environments in the human body — the digestive system.
An expert system for destroying peptides
Most people picture the stomach as a holding container — somewhere food waits before moving on. In reality, it is one of the body’s most capable chemical processing plants, and every day it carries out a formidable task: dismantling the complex molecules in food into building blocks small enough to absorb. Proteins become amino acids. Fats become fatty acids. Carbohydrates become simple sugars.
The enzymes that do this work have been refined over hundreds of millions of years to recognise and cut apart proteins and peptides with precision. Unfortunately, precision is not the same as discernment. These enzymes cannot tell a food protein from a peptide medicine. To the digestive system, a grilled chicken breast and a dose of semaglutide both look like the same thing: a chain of amino acids waiting to be taken apart. One is dinner. The other took two decades and billions of dollars to design. The enzymes do not care about the difference.
Swallow an injectable GLP-1 medicine whole, unprotected, and almost none of the active drug would survive the journey. Long before it reached the bloodstream, it would become nothing more than another source of amino acids.
Three separate battles, and most peptides lose the first one
Scientists often describe oral drug delivery as a transport problem. For a peptide, it is more accurate to call it an obstacle course. Before it can do any good, an oral peptide medicine must win three separate battles — and most candidates never make it past the first [1].
Battle One — survive the acid.
Battle Two — cross the intestinal wall.
Battle Three — stay active long enough in the blood to work.
Battle One: surviving the stomach. The stomach is an acidic environment, with a pH that can fall to around 1–2 — strong enough to help digest food and kill many microorganisms. For a fragile peptide, this is an unforgiving place: acid can distort its three-dimensional shape, making it easier for digestive enzymes such as pepsin to cut the chain into fragments. Once the chain breaks, the medicine stops working. This is why peptide drugs cannot simply be pressed into an ordinary tablet the way aspirin can — they need a formulation built specifically to protect them through the earliest minutes of digestion.
Battle Two: crossing the intestinal wall. Suppose the peptide somehow survives the acid. The next obstacle is more surprising than the first. Nutrients do not pass through the intestinal lining like water through a sponge — the lining is a highly selective barrier, built to absorb what the body needs while keeping bacteria, toxins and unwanted molecules out. Think of it as an airport security checkpoint: small molecules such as glucose and many conventional drugs pass through with relative ease, while large peptides face a far stricter inspection. The cells lining the intestine are sealed together by microscopic junctions that leave almost no space for a large molecule to slip between them. Most are turned away.
Battle Three: staying active long enough to work. Reaching the bloodstream is not the finish line. As the previous article in this series set out, the body runs its own clean-up crew: natural GLP-1 survives only one to two minutes before the enzyme DPP-4 breaks it down. Scientists must therefore solve two problems at once — get the peptide across the gut wall, and redesign it so it survives long enough, once inside, to do any good. Semaglutide’s own solution to that third battle — resisting DPP-4 and binding to albumin to circulate for roughly a week — is a genuine engineering achievement. It just doesn’t help with battles one and two, which is exactly why the injectable version exists at all.
Bioavailability: the number that keeps formulation scientists up at night
Drug developers use a single word to describe how successfully a medicine reaches the bloodstream: bioavailability. The concept is simpler than it sounds. Imagine sending a hundred carefully packaged parcels. If ninety arrive intact, the delivery system is excellent. If only one arrives, something has gone badly wrong.
Medicines work the same way. An intravenous injection has a bioavailability of 100%, because every molecule enters the circulation directly. Many conventional tablets achieve bioavailabilities of 50–90%, depending on the drug. Peptide medicines tell a very different story: without specialised formulation technology, oral peptide bioavailability is often below one percent [2] — ninety-nine parcels lost for every one that arrives.
That single figure is why an entire field of pharmaceutical science exists to chase it upward: permeation enhancers, protective coatings, carrier chemistries, and delivery vehicles of every description, all aimed at getting a few more parcels through customs intact. It is also the problem Ibumix works on — not by re-engineering the peptide itself, as semaglutide’s own designers did so effectively, but by re-engineering the vehicle that carries a drug through the gut wall in the first place.
The next article in this series looks at how the industry has actually tried to solve this problem — the first oral GLP-1 tablet to reach the market, the chemistry trick that got it there, and why even a genuine breakthrough still leaves most of the dose behind.
Sources
- [1] Brayden DJ, Alonso MJ. Oral delivery of peptides: opportunities and issues for translation. Advanced Drug Delivery Reviews (2016). pubmed.ncbi.nlm.nih.gov
- [2] Renukuntla J, Vadlapudi AD, Patel A, Boddu SHS, Mitra AK. Approaches for enhancing oral bioavailability of peptides and proteins. International Journal of Pharmaceutics (2013). pubmed.ncbi.nlm.nih.gov
Ibumix is developing a series of new liquid drug delivery platforms built on glyceryl caprate (GCC) lipid chemistry, with a patent estate covering the underlying formulation and device.